A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Conditions: Atopic Dermatitis Interventions: Drug: BxC-I17e; Drug: Placebo Sponsors: Brexogen Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials